Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05984511 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 1, 2023 to Aug 30, 2023
    • Collaborators revised (5)
    v4
  2. Start date: Aug 1, 2023 to Sep 1, 2023v3
  3. Collaborators reorderedv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). The investigators confirmed that the combination therapy yielded better survival data than the combined administration of Atezolizumab/Bevacizumab and TACE (TACE-AB) in patients with advanced HCC and Type I/II PVTT (Based on Cheng's PVTT classification).
Trial Details
NCT Number NCT05984511
Lead Sponsor Third Affiliated Hospital, Sun Yat-Sen University
Collaborators: Sun Yat-Sen University Cancer Center, Fifth Affiliated Hospital, Sun Yat-Sen University, Second Affiliated Hospital of Guangzhou Medical University, Maoming People's Hospital, Shandong Province Third hospital
Conditions
(from sponsor)		 Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
Related terms Carcinoma, Hepatocellular
Enrollment 234 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov